“Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties - The Lancet” plus 1 more

“Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties - The Lancet” plus 1 more

Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties - The Lancet

Posted: 29 Oct 2020 04:36 PM PDT

[unable to retrieve full-text content]Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties  The Lancet

DRIVE ReDIRECT: Program Seeks to Develop Countermeasures Against Chemical Threats - Global Biodefense

Posted: 31 Oct 2020 02:40 PM PDT

The rapid availability of effective medical countermeasures against chemical exposures, from either accidents or chemical weapons attack, is critical in the treatment of their acute health effects following exposures.

The ReDIRECT Program is a new initiative from the Biomedical Advanced Research and Development Authority (BARDA) which aims to identify existing, commonly available therapeutics that can be used to save lives during a chemical emergency.

Under this new EZ BAA Area of Interest (AOI), BARDA will review concise abstract submissions for funding development that repurposes easily accessible therapeutics as medical countermeasures against threats such as chlorine gas, opioids, nerve agents, and others.

The ideal medical countermeasure is easily administered in a mass-casualty situation and has rapid efficacy as a post-exposure therapy, which requires easy access within hospitals, pharmacies, and the community. Drug repurposing, or label expansion, is a strategy that is used to identify new uses for FDA approved or late-stage investigational therapeutics that are outside of their original clinical indication. The identification of existing compounds for repurposing holds the potential to expand current response capabilities to chemical threats, as well as potentially mitigating the costs and risks associated with conventional drug discovery.

Repurposing drugs will ensure that these therapeutics are easily accessible during an emergency and reduce the reliance on centralized stockpiles or logistically-challenging forward deployment programs. Candidates for repurposing will focus on treating the symptoms associated with exposure to the chemical threat, rather than the agent.

The ReDIRECT program is focused on repurposing therapeutics against any of the following agents:

Pulmonary Agents: Development of medical countermeasures to prevent and treat lung damage (including pulmonary edema, pneumonitis, and fibrosis) resulting from exposure to agents such as chlorine, sulfur mustard and phosgene.

Opioids: Development of medical countermeasures to treat life-threatening respiratory depression caused by opioid overdose. These post-exposure treatments should be quick-acting and effective against a variety of opioids, including synthetic opioids such as Fentanyl. Candidates should have a mechanism of action different from existing opioid receptor antagonists.

Vesicants: Development of medical countermeasures that limit harmful aspects of exposure to vesicating agents such as sulfur mustard and Lewisite. Particular preference is given to drugs with potential to ameliorate the long term effects of exposure including Mustard Gas Keratopathy.

Blood/Metabolic Agents: Development of medical countermeasures to treat acute poisoning from agents such as cyanides. Antidotes should be easily administered by first responders in personal protective equipment. Preference is given to those cyanide antidotes that are also effective against smoke inhalation-related exposure.

Nerve Agents and Organophosphorus (OP) Pesticides: Development of medical countermeasures to treat life-threatening and long-term effects of nerve agents and OP pesticides. Antidotes should be easily administered by first responders in personal protective equipment.

Computational approaches to identify candidates for drug repurposing: Development of improved methods to rapidly identify FDA approved or late stage candidate compounds that can be repurposed against any of the aforementioned chemical threats.

The effort is a collaboration of BARDA's Division of Research, Innovation, and Ventures (DRIVe) and the Chemical, Biological, Radiological and Nuclear (CBRN) Division.

The EZ-BAA was created to provide a streamlined process through which BARDA, and DRIVe specifically, can review and accept applications for development funding of transformative products and technologies to protect Americans from health security threats. The application process is both business-friendly and easy to follow.

Since its inception, the EZ-BAA has helped transform BARDA's contracting process and provide innovators, entrepreneurs, and organizations with a simplified and rapid mechanism to partner with the BARDA.

For additional information, see solicitation BAA-20-100-SOL-0002.

Comments

Post a Comment

Popular posts from this blog

His Apple Watch warned of an irregular heart rate. Turns out he was having a heart attack | Globalnews.ca - Global News Toronto

Image
A Nova Scotia man is thanking a digital watch for saving his life. Travis Chalmers, of Elmsdale, N.S., said he was outside playing road hockey with his son when he suddenly experienced a "warm sensation" in his chest area and a splitting headache. "I just thought it was a flu or cold coming on and my seasonal allergies had been kicking in. I thought it was flu-like symptoms and shrugged it off," he said. But to Chalmers' surprise, an otherwise laidback afternoon eventually took a scary turn when he glanced at his wrist. A notification from his Apple Watch led him to discover he was experiencing a heart attack. "About a half hour later, I'm laying down with my daughter and my heart rate is still beating out of my chest," he continued, adding that he monitored his heart rate on his Apple Watch for the next few hours. The watch indicated that he was experiencing atrial fibrillation, a rapid heart rhythm that can increase the ris...
Read more

“Opioids in America, Part 3: The other side of the crisis - Greeley Tribune” plus 1 more

Image
“Opioids in America, Part 3: The other side of the crisis - Greeley Tribune” plus 1 more Opioids in America, Part 3: The other side of the crisis - Greeley Tribune Posted: 31 Oct 2020 04:20 PM PDT Editor's Note: This is Part 3 of a three-part series looking into the opioid epidemic across the U.S., rehabilitation options in Weld County and stories from people who have overcome or are currently fighting addiction to opioids. Like many things, there's another side to the opioid crisis. While the addiction to opioids is a problem that needs to be addressed, people who are using the drugs exclusively as prescribed — and who still truly need it from a medical perspective — have been swept up in what some have seen as government's knee-jerk reaction to the crisis. In having their ability limited to get the drugs they need in order to function, many of these patients are left suffering debilitating pain. Richard Mark VanWormer w...
Read more

“A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times” plus 1 more

Image
“A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times” plus 1 more A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times Posted: 12 Dec 2019 11:25 AM PST It was chest pain that brought the 34-year-old woman to the emergency room at Montefiore Medical Center in the Bronx. She'd been coughing for days, but that morning the pain was so bad she was worried that it had turned into pneumonia. She tried to tough it out, but when it was no better by the end of the day, she decided to go to the E.R. It took a few hours, but finally the physician assistant caring for her in the E.R. brought some good news. She didn't have pneumonia; she didn't have a clot in her lungs. This was just muscle strain from coughing. The year before, she was told she had asthma. She was given inhalers to stop the coughing and wheezing, but they didn't seem to do much. So she didn'...
Read more